This postdoctoral training grant in Clinical Therapeutics is a vital component of the Committee on Clinical Pharmacology and Pharmacogenomics (CCPP), as well as the new Center for Personalized Therapeutics (CPT) at The University of Chicago (UC). The program provides an infrastructure for the postdoctoral training of both clinicians and translational scientists in clinical pharmacology, therapeutics, an pharmacogenomics. The CCPP, a formal interdepartmental unit, is responsible for the training program, which is also accredited by the American Board of Clinical Pharmacology (ABCP). M. Eileen Dolan, Ph.D. (Chair of CCPP) directs the program along with Michael Maitland, M.D., Ph.D. (Associate Director of Training Program) and Mark Ratain, M.D. (Director of the Center for Personalized Therapeutics and the ABCP-accredited Training Program). The CCPP leadership team is assisted by an Executive Committee, a Fellowship Selection Committee, and an Advisory Committee. The program fulfills a unique niche within UC, providing focused training in translational pharmacology to trainees with either a clinical or scientific background (some trainees have had both a clinical and PhD degree). Although the primary mission is to prepare clinicians for a research career in clinical pharmacology, the program also has successfully trained scientists in translational clinical pharmacology. Most trainees have medical degrees and are board eligible in their area of specialty; other trainees hold Ph.D and/or Pharm.D. degrees. The program is primarily focused on research training, under the supervision of a mentor selected by the trainee (and approved by the Executive Committee). The research training is supplemented with formal coursework and participation in seminars, journal clubs, directed readings and teaching. The trainee will participate in activities such as the Clinical Pharmacology Consult Service, the Institutional Review Board, and the Pharmacy and Therapeutics Committee. A maximum of 10% effort will be allowed for clinical responsibilities in the area of the trainee's specialty. Upon completion of this program, the trainee is expected to become accomplished in basic research methodology, experimental design, and data interpretation and presentation, and be prepared for a competitive academic research career, as well as certification in Clinical Pharmacology.

Public Health Relevance

This postdoctoral training grant in Clinical Therapeutics is a vital component of the Committee on Clinical Pharmacology and Pharmacogenomics (CCPP), as well as the new Center for Personalized Therapeutics (CPT) at The University of Chicago (UC). The program provides an infrastructure for the postdoctoral training of both clinicians and translational scientists in clinical pharmacology, therapeutics, and pharmacogenomics. The CCPP, a formal interdepartmental unit, is responsible for the training program, which is also accredited by the American Board of Clinical Pharmacology (ABCP). The training program fulfills a unique niche within UC, providing focused training in translational pharmacology to trainees with either a clinical or scientific background (some trainees have had both a clinical and PhD degree). Although the primary mission is to prepare clinicians for a research career in clinical pharmacology, the program also has successfully trained scientists in translational clinical pharmacology. Upon completion of this program, the trainee is expected to become accomplished in basic research methodology, experimental design, and data interpretation and presentation, and be prepared for a competitive academic research career, as well as certification in Clinical Pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007019-43
Application #
9729724
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Garcia, Martha
Project Start
1978-07-01
Project End
2020-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
House, Larry; Seminerio, Michael J; Mirkov, Snezana et al. (2018) Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 48:973-983
Sokol, Elizabeth A; Engelmann, Roger; Kang, Wenjun et al. (2018) Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer 65:e27417
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Arndt, David L; de Wit, Harriet (2017) Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults. Cannabis Cannabinoid Res 2:105-113
Applebaum, Mark A; Desai, Ami V; Glade Bender, Julia L et al. (2017) Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs 5:355-368
Sweis, Randy F; Luke, Jason J (2017) Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res 120:1-9
Sweis, Randy F; Ratain, Mark J (2017) Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol 35:260
Pettit, Kristen; Odenike, Olatoyosi (2017) Novel Therapies for Myelofibrosis. Curr Hematol Malig Rep 12:611-624
Eadon, Michael T; Hause, Ronald J; Stark, Amy L et al. (2017) Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci 18:
Applebaum, Mark A; Vaksman, Zalman; Lee, Sang Mee et al. (2017) Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 72:177-185

Showing the most recent 10 out of 107 publications